Quantcast

Latest Thrombosis Stories

2014-03-25 23:00:43

The Firm is investigating testosterone treatment lawsuits on behalf of men who suffered heart attacks, strokes and other dangerous cardiovascular problems, allegedly due to the use of drugs like Testim and AndroGel. New York, New York (PRWEB) March 25, 2014 A second testosterone treatment lawsuit (http://www.testosteronelawsuitcenter.com/) has been filed in Pennsylvania on behalf of a man who allegedly suffered serious cardiovascular problems due to his use of Testim. According to the...

2014-03-24 20:23:44

The International Society on Thrombosis and Haemostasis partners with thrombosis related organizations from every continent to launch World Thrombosis Day focused on single cause of top 3 cardiovascular deaths worldwide CHAPEL HILL, N.C., March 24, 2014 /PRNewswire-USNewswire/ -- Bringing together nations and local communities to tackle thrombosis, the quiet, underlying disorder that is the common mechanism of the world's three top cardiovascular killers - heart attack, stroke and venous...

2014-03-24 08:28:21

Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA(TM)-AF registry RIDGEFIELD, Conn., March 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from three company-sponsored PRADAXA studies will be presented at the American College of Cardiology 63(rd) Annual Scientific Session (ACC.14) in Washington, D.C., March 29 to 31, 2014. An oral presentation will...

2014-03-24 08:27:40

- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials(1,2,3,4) TOKYO, March 24, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) enrolled in two phase...

2014-03-24 08:26:49

Results Show Highest Rate of Control Ever Observed with Warfarin in Real-world Setting, Surpassing Thresholds for Cost-Effectiveness of Newer Agents Identified in Five Recent Independent Studies WALTHAM, Mass., March 24, 2014 /PRNewswire/ -- Alere Inc. (NYSE: ALR) today announced the publication of the largest-ever study of warfarin patient self-testing, which demonstrated that weekly International Normalized Ratio (INR) testing significantly improves control of warfarin, as measured...

2014-03-20 00:21:35

Insufficient medical care of blood clots in the extremities is prevalent, but Dr. Malekmehr of the California Institute for Deep Venous Thrombosis takes an active approach LOS ANGELES, March 19, 2014 /PRNewswire/ -- A blood clot in the lower part of the body, or deep vein thrombosis, is a well-known but often misunderstood syndrome despite its potentially grave consequences. Fortunately, widely respected board certified cardiovascular surgeon Dr. Farshad Malekmehr of the California...

2014-03-18 23:02:37

Merck & Co. Has Agreed to Pay $100 Million to Settle Thousands of NuvaRing Blood Clot Lawsuits Now Pending in State and Federal Courts, But it is Contingent on 95% Approval of Women Plaintiffs. Columbus, OH (PRWEB) March 18, 2014 Wright & Schulte LLC, an experienced medical device injury law firm representing numerous women in NuvaRing lawsuits, reports that the deadline for opting out of the recently announced NuvaRing settlement has been extended until March 25, 2014. According...

2014-03-03 23:02:09

Despite the FDA's recent rejection of Xarelto, Dr. Henry Mentz and the Aesthetic Center for Plastic Surgery plan to continue research. Houston, TX (PRWEB) March 03, 2014 Last month, the FDA denied approval of new uses for Johnson & Johnson’s blood thinning drug Xarelto. Dr. Mentz, of the Aesthetic Center for Plastic Surgery, will still continue his research on the drug, however. Xarelto was seeking clearance to treat patients with acute coronary syndrome (ACS) when it was...

2014-02-26 23:02:53

The Firm is investigating testosterone treatment lawsuits on behalf of men who suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious cardiovascular problems, allegedly due to AndroGel and other low testosterone therapies. New York, NY (PRWEB) February 26, 2014 As testosterone lawsuits (http://www.testosteronelawsuitcenter.com/ ) involving AndroGel continue to mount, Bernstein Liebhard LLP notes that a leading consumer advocacy group is pushing...

2014-02-19 23:02:44

The Firm is evaluating testosterone treatment lawsuits on behalf of individuals who allegedly suffered heart attacks, strokes, deep vein thrombosis, and pulmonary embolism due to their use of prescription “Low T” therapies like AndroGel. New York, New York (PRWEB) February 19, 2014 Testosterone treatment lawsuits (http://www.testosteronelawsuitcenter.com/) involving prescription medications like AndroGel continue to mount in courts throughout the country, Bernstein Liebhard LLP...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related